As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational activities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing health care goods or services that have occurred within 24 months from the start of or during the production of the work and that are relevant to the author’s content. If an author has such an interest, then they must disclose the name of the commercial interest and nature of the relationship (eg, consultant or grantee). An author who has no such financial relationship must declare that they have nothing to disclose. The intent of this disclosure is not to prevent an author with a significant financial or other relationship from making a presentation, but rather to provide readers with information that they can use to make their own judgments. It remains for the audience to determine whether the author’s interests or relationships may influence the work with regard to exposition or conclusion.
Disclosures of financial relationshipsChapter 1, Molecular concepts in hematology and cellular basis of hematopoiesis
Berthold Göttgens: no competing financial interest. Gabriel Ghiaur: no competing financial interest.
Chapter 2, Consultative hematology 1: hospitalbased and selected outpatient topicsJennifer R. Green: honoraria: North American Thrombosis Forum, Scripps Health. Board membership: EPIC Hematology Steering Board. Grant funding: Health Resources and Services Administration, Centers for Disease Control and Prevention, Patient Centered Outcomes Research Institute, American Thrombosis and Hemostasis Network. Shannon L. Carpenter: Consultancy: CSL Behring, Kedrion Biopharmaceuticals, HEMA Biologics; Novo Nordisk Pharmaceuticals, Inc; Bayer; Genentech. Membership on board of directors: Hemostasis and Thrombosis Research Society. Grant funding: Shire, CSL Behring.
Chapter 3, Consultative hematology 2: women’s health issuesLeslie Skeith: research funding: CSL Behring. Honoraria: Leo Pharma, Sanofi. Molly Weidner Mandernach: no competing financial interest. Andra H. James: research funding: Coagulant Therapeutices. Consulting: Cerus, Octapharma, Tremeau, Hemosonics, Coagulant Therapeutics.
Chapter 4, Hematopoietic growth factorsSophie Park: research support: Novartis, Pfizer, Takeda, Sandoz, and BMS for research in myelodysplastic syndromes. Gerald A. Soff: research support: Amgen, Dova/Sobi Pharmaceuticals, and Janssen Scientific Affairs. Advisory boards (in the past 5 years: Amgen, Janssen Scientific Affairs, Bayer Pharmaceuticals, Dova Pharmaceuticals, Bristol Myers Squibb, Pfizer, Novartis, Anthos Therapeutics, and Hengrui (USA) Ltd.
Chapter 5, Iron physiology, iron overload, and the porphyriasElizabeta Nemeth: stock ownership: Intrinsic LifeSciences and Silarus Therapeutics. Consultancy: Protagonist Therapeutics, Ionis Pharmaceuticals, Disc Medicine, and Astra- Zeneca-Fibrogen. Carol Mathew: no competing financial interest.
Chapter 6, Acquired underproduction anemiasJacquelyn M. Powers: research funding to her institution: American Regent. Maria Domenica Cappellini: no competing financial interest.
Chapter 7, Thalassemia, sickle cell disease, and other hemoglobinopathiesPayal Desai: advisory Board: Pfizer, GBT, Takeda, and Forma. Speaker & Research Project: Novartis. Rakhi Naik: Rigel, Elsevier. Jeffrey Lebensburger: consultant: Novartis, Emmaus, Forma Therapeutics, Agios.
Chapter 8, Hemolytic anemias excluding hemoglobinopathiesKevin H. M. Kuo: consultancy: Agios, Alexion, Apellis, Aruvant, Bioverativ/Sanofi, Bluebirdbio, Celgene/BMS, Forma, Novartis, and Pfizer. Member of the scientific advisory board: Agios. Honoraria: Agios, Alexion. and Novartis. Research support: Pfizer. Scientific collaboration: Abfero and Phoenicia Biosciences. Samuel A. Merrill: member of scientific advisory board: True North Therapeutics, Alexion, and Rigel.
Chapter 9, Thrombosis and thrombophiliaPaul Monagle: no competing financial interest. Bethany Samuelson Bannow: no competing financial interest.
Chapter 10, Bleeding disordersSven Olson: no competing financial interest. Riten Kumar: consultancy: Bayer.
Chapter 11, Disorders of platelet number and functionHanny Al-Samkari: consultancy: Agios, Dova, Argenx, Sobi, and Rigel. Research funding: Amgen, Agios, and Dova. Michele P. Lambert: advisory board membership: Octapharma and Shionogi. Consultancy: Amgen, Novartis, Shionogi, Dova, Principia, Argenx, Rigel, and Bayer. Research funding: Sysmex, Novartis, Rigel, and AstraZeneca.
Chapter 12, Laboratory hematologyKristi J. Smock: no competing financial interest. Kenneth D. Friedman: consultancy: Instrumentation Laboratory, Siemens, and Takeda.
Chapter 13, Transfusion medicineMichelle P. Zeller: medical officer with Canadian Blood Services. Honoraria: Pharmacosmos, Pfizer, and American Society of Hematology; research funding: Canadian Institute of Health Research, Canadian Blood Services, and Pfizer Global Medical Grants. Stella T. Chou: consultancy: Platelet- Bio. Honoraria: American Society of Hematology, Wolters Kluwer, and Engage Health Media. Research funding: National Institutes of Health and Hyundai Hope on Wheels.
Chapter 14, Hematopoietic cell transplantation and cellular therapyIrum Khan: honoraria: Takeda and Celgene. Nirav N. Shah: honoraria and/or travel support: Incyte, Celgene, Lily, and Miltenyi Biotec. Membership on scientific advisory board: Lilly, Kite, Celgene, Legend, Epizyme, Seattle Genetics, and TG Therapeutics. Equity ownership in: Exelixis and Geron. Institutional research support for clinical trials: Miltenyi Biotec. Matthew Ulrickson: no competing financial interest.
Chapter 15, Myeloid disorders and inherited bone marrow failure syndromesBoglarka Gyurkocza: clinical trial support: Actinium Pharmaceuticals. Marcin Wlodarski: no competing financial interest. Cynthia E. Dunbar: research and clinical trial support: Novartis.
Chapter 16, Chronic myeloid leukemiaKendra L. Sweet: research funding: Incyte. Membership on advisory boards: Novartis, Bristol Myers Squibb and Arog. Honorarium: Astellas. Ehab L. Atallah: research funding: Novartis and Takeda. Consultancy: Pfizer, Celgene, Novartis, and Takeda.
Chapter 17, Myeloproliferative neoplasmsAngela Fleischman: membership on advisory board: PharmaEssentia, CTI, and BMS. Kristen Pettit: membership on an advisory board: PharmaEssentia and Kura Oncology.
Chapter 18, Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromesBhumika J. Patel: speaker bureau: Alexion and Apellis. Catherine Smith: research funding: AbbVie. Clinical trial: Celgene.
Chapter 19, Acute myeloid leukemiaNeerav Shukla: no competing financial interest. Michael F. Walsh: no competing financial interest. Roland B. Walter: laboratory research grants and/or clinical trial support: Amgen, Aptevo, Celgene, ImmunoGen, Janssen, Jazz, MacroGenics, Pfizer, and Selvita. Ownership interest in: Amphivena. Consultancy: Amphivena, Astellas, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Kite, Kronos, and MacroGenics.
Chapter 20, Acute lymphoblastic leukemia and lymphoblastic lymphomaOliver G. Ottmann: research funding: Incyte and Amgen. Liora Schultz: no competing financial interest.
Chapter 21, Hodgkin lymphomaCeleste Bello: research advisory board (with honorarium): Seattle Genetics. Pamela B. Allen: research advisory board (with honorarium): Bayer, Daichii Sankyo, Imbrium, and Kyowa Kirin. Research funding: Kyowa Kirin.
Chapter 22, Indolent non-Hodgkin lymphomasSairah Ahmed: no competing financial interest. David T. Yang: consultancy: Novartis.
Chapter 23, Aggressive non-Hodgkin and Burkitt lymphomaAllison Rosenthal: no competing financial interest. Amitkumar Mehta: research funding: Incyte, Takeda, Forty Seven Inc/Gilead, Juno Pharmaceuticals/BMS, Celgene/BMS, OncoTartis, Innate Pharmaceuticals, SeaGen, TG Therapeutics, Affimed, Merck, Kite/Gilead, Roche-Genentech, and ADC Therapeutics. Consultancy, speaker, or advisory board member: Gilead, AstraZeneca, Pharmacyclics, SeaGen, Morphosys/Incyte, TG Therapeutics, Kyowa Kirin, and Rigel Pharmaceuticals.
Chapter 24, Chronic lymphocytic leukemia/small lymphocytic lymphomaTanya Siddiqi: speaker: Pharmacyclics, AstraZeneca, Bristol Myers Squibb, and Janssen. Advisor: Pharmacyclics, Astra- Zeneca, Bristol Myers Squibb, Juno Therapeutics, Celgene, Kite Pharma, and BeiGene. Jennifer Woyach: consultant: Pharmacyclics, Janssen, AbbVie, AstraZeneca, BeiGene, Arqule, and Loxo.
Chapter 25, Plasma cell disordersCaitlin Costello: consultancy: BMS, Janssen, Takeda, Karyopharm, and Oncopeptides. Research funding: Celgene, Takeda, Pfizer, and Poseida. Rafael Fonseca: consultancy: Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Karyopharm, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK, and AbbVie. Scientific advisory board member: Adaptive Biotechnologies, Caris Life Sciences, and OncoTracker.
Discussion of off-label drug use
In compliance with ACCME policy, the American Society of Hematology requires all authors to disclose any discussion of off-label drug use in their chapters.